Patient Advantage Tonawanda, NY - 14150

Patient Advantage is categorized under Commercial Medical Research in Tonawanda, NY and active since 2004.

Patient Advantage was established in 2004, and today employs 1 to 4, earning $500.000 to $999.999 per year. This is a Commercial Medical Research business, which does work in the B2B market, and is classified as a Commercial Medical Research, under code number 6219991 by the NAICS.

If you are seeking more information, feel free to contact Paul Bluestein at the company’s single location by writing to 2274 Niagara Falls Boulevard, Tonawanda, New York NY 14150 or by phoning (716) 695-2213. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.

Business Name: Patient Advantage
Contact Person: Paul Bluestein
Address: 2274 Niagara Falls Boulevard, Tonawanda, New York 14150
Phone Number: (716) 695-2213
Website Address: patientadvantage.com
Annual Revenue (USD): $500.000 to $999.999
Founded: 2004
Location Type: Single Location
Employee Number: 1 to 4
Business Type: B2B (Business to Business)
Business Category: Commercial Medical Research
SIC Code: 8731
NAICS Code: 6219991
Share This Business:

Patient Advantage was started in 2004 to provide professional Commercial Medical Research under the SIC code 8731 and NAICS code 6219991. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $500.000 to $999.999 per annum.

Feel free to contact Paul Bluestein for inquiries that concern Patient Advantage by calling the company number (716) 695-2213, as your correspondence is most welcome. Additionally, the physical location of the single location of Patient Advantage can be found at the coordinates 43.016158,-78.822168 as well as the street address 2274 Niagara Falls Boulevard in Tonawanda, New York 14150.

For its online presence, you may visit Patient Advantage’s website at patientadvantage.com and engage with its social media outlets through on Twitter and on Facebook.